MoonLake Immunotherapeutics Management
Management criteria checks 2/4
MoonLake Immunotherapeutics' CEO is Jorge da Silva, appointed in Apr 2022, has a tenure of 3.25 years. total yearly compensation is $1.41M, comprised of 49.7% salary and 50.3% bonuses, including company stock and options. directly owns 4.85% of the company’s shares, worth $169.54M. The average tenure of the management team and the board of directors is 1.5 years and 3.3 years respectively.
Key information
Jorge da Silva
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 49.66% |
| CEO tenure | 3.3yrs |
| CEO ownership | 4.9% |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Is MoonLake Immunotherapeutics (NASDAQ:MLTX) Using Debt In A Risky Way?
Jul 26
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
Jun 03We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth
Apr 09MoonLake Immunotherapeutics: A Buy At Dips
Apr 08Are Investors Undervaluing MoonLake Immunotherapeutics (NASDAQ:MLTX) By 39%?
Jan 20We're Not Very Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Rate
Dec 16MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold
Oct 13MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$145m |
| Dec 31 2024 | US$1m | US$698k | -US$119m |
| Sep 30 2024 | n/a | n/a | -US$81m |
| Jun 30 2024 | n/a | n/a | -US$55m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | US$1m | US$586k | -US$36m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$48m |
| Dec 31 2022 | US$4m | US$460k | -US$50m |
| Sep 30 2022 | n/a | n/a | -US$58m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Dec 31 2021 | US$5m | US$230k | -US$64m |
Compensation vs Market: Jorge's total compensation ($USD1.41M) is below average for companies of similar size in the US market ($USD7.50M).
Compensation vs Earnings: Jorge's compensation has increased whilst the company is unprofitable.
CEO
Jorge da Silva (48 yo)
Dr. Jorge Santos da Silva, Ph D., is a Co-Founder of MoonLake Immunotherapeutics (Alternate name MoonLake Immunotherapeutics AG) and has served as the Chief Executive Officer since April 2022. Dr. da Silva...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.3yrs | US$1.41m | 4.85% $ 169.5m | |
| Co-Founder & Chief Scientific Officer | 3.3yrs | US$1.30m | 4.86% $ 169.7m | |
| Chief Financial Officer | 3.3yrs | US$1.03m | 0.97% $ 34.0m | |
| Chief Operations Officer | 1.5yrs | no data | no data | |
| Director of Investor Relations & External Communications | 1.5yrs | no data | no data | |
| General Counsel | 2.6yrs | no data | no data | |
| Senior Director Legal & Compliance | 1.5yrs | no data | no data | |
| Vice President of Marketing | 1.5yrs | no data | no data | |
| Director of HR | 1.5yrs | no data | no data | |
| Chief Clinical Development Officer | 3.8yrs | no data | no data | |
| Chief of Staff to the Executive Board | 1.5yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | no data | no data |
Experienced Management: MLTX's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.3yrs | US$1.41m | 4.85% $ 169.5m | |
| Independent Chairman of the Board | 3.3yrs | US$315.51k | 0.27% $ 9.5m | |
| Independent Director | 3.3yrs | US$287.51k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$281.01k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$300.01k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$277.51k | 0% $ 0 |
Experienced Board: MLTX's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/27 10:38 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MoonLake Immunotherapeutics is covered by 16 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Samantha Lynn Semenkow | Citigroup Inc |